Buy Regorafenib 40 mg online, Buy Stivarga online

Regonix is the alternative & generic version of Stivarga by Bayer. Regonix is manufactured by Beacon Pharmaceuticals Bangladesh which is the biggest pharmaceutical company in Bangladesh.

Regonix (Stivarga) Regorafenib by Beacon Pharma is used to treat Colon cancer. It is also used to treat Liver Cancer and Gastrointestinal Stromal Tumor(GIST).

Regonix（Stivarga）is a generic oncologic prescription medicine for Colorectal Cancer, Gastrointestinal Stromal Tumors and Hepatocellular Carcinoma from Beacon.

Indications

Colorectal Cancer: Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild- type, an anti-EGFR therapy.

Gastrointestinal Stromal Tumors: Regorafenib is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

Hepatocellular Carcinoma: Regorafenib is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Therapeutic Class

Targeted Cancer Therapy

Pharmacology

Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, metastasis and tumor immunity.

In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E.

Dosage

Recommended Dose: The recommended dose is 160 mg Regorafenib (four 40 mg tablets) taken orally once daily for the first 21 days of each 28-day cycle. Continue treatment until disease progression or unacceptable toxicity.

Take Regorafenib at the same time each day. Swallow tablet whole with water after a low-fat meal that contains less than 600 calories and less than 30% fat. Do not take two doses of Regorafenib on the same day to make up for a missed dose from the previous day.

Dose Modifications: If dose modifications are required, reduce the dose in 40 mg (one tablet) increments; the lowest recommended daily dose of Regorafenib is 80 mg daily.

Administration

Advise patients to swallow the Regorafenib tablet whole with water at the same time each day following a low-fat meal. Inform patients that the low-fat meal should contain less than 600 calories and less than 30% fat

Advise patients to store medicine in the original container. Do not place medication in daily or weekly pill boxes. Discard any remaining tablets 7 weeks after opening the bottle. Tightly close bottle after each opening and keep the desiccant in the bottle

Interaction

Effect Of Strong CYP3A4 Inducers On Regorafenib: Co-administration of a strong CYP3A4 inducer with Regorafenib decreased the plasma concentrations of Stivarga, increased the plasma concentrations of the active metabolite M-5.

Effect Of Strong CYP3A4 Inhibitors On Regorafenib: Co-administration of a strong CYP3A4 inhibitor with Stivarga increased the plasma concentrations of regorafenib and decreased the plasma concentrations of the active metabolites M-2 and M-5, and may lead to increased toxicity.

Effect Of Regorafenib On Breast Cancer Resistance Protein (BCRP) Substrates: Co-administration of Regorafenib with a BCRP substrate increased the plasma concentrations of the BCRP substrate.

Contraindications

None

Side Effects

Common side effects are Hepatotoxicity, Infections, Hemorrhage, Gastrointestinal Perforation or Fistula, Dermatological Toxicity, Hypertension, Cardiac Ischemia and Infarction, Reversible Posterior Leukoencephalopathy Syndrome (RPLS)

Pregnancy & Lactation

Pregnancy: Based on animal studies and its mechanism of action, Stivarga can cause fetal harm when administered to a pregnant woman. There are no available data on Regorafenib use in pregnant women.

Administration of regorafenib was embryolethal and teratogenic in rats and rabbits at exposures lower than human exposures at the recommended dose, with increased incidences of cardiovascular, genitourinary, and skeletal malformations.

Lactation: There are no data on the presence of regorafenib or its metabolites in human milk, the effects of regorafenib on the breastfed infant, or on milk production. In rats, Stivarga and its metabolites are excreted in milk.

Precautions & Warnings

Severe hepatic impairment. Pregnancy and lactation.

Use in Special Populations

Pediatric Use: The safety and efficacy of Stivarga in pediatric patients less than 18 years of age have not been established.

Geriatric Use: Of the 1142 Stivarga -treated patients enrolled in randomized, placebo-controlled trials, 40% were 65 years of age and over, while 10% were 75 and over. No overall differences in efficacy were observed between these patients and younger patients.

Hepatic Impairment: No dose adjustment is recommended in patients with mild or moderate hepatic impairment. Closely monitor patients with hepatic impairment for adverse reactions.

Renal Impairment: No dose adjustment is recommended for patients with renal impairment. The pharmacokinetics of regorafenib have not been studied in patients who are on dialysis and there is no recommended dose for this patient population

Overdose Effects

The highest dose of Stivarga studied clinically is 220 mg per day. The most frequently observed adverse drug reactions at this dose were dermatological events, dysphonia, diarrhea, mucosal inflammation, dry mouth, decreased appetite, hypertension, and fatigue.

Storage Conditions

Store Stivarga at 25°C; excursions are permitted from 15 to 30°C. Store tablets in the original bottle and do not remove the desiccant. Keep the bottle tightly closed after first opening. Discard any unused tablets 7 weeks after opening the bottle.